US2014329776A1PendingUtilityA1

Mitochondria-Targeted Antioxidants for Treatment of Age-Related Brain Disorders

32
Individually held — no corporate assignee on recordPriority: Sep 21, 2012Filed: Sep 21, 2012Published: Nov 6, 2014
Est. expirySep 21, 2032(~6.2 yrs left)· nominal 20-yr term from priority
Inventors:Maxim V. SkulachevVladimir P. SkulachevMaxim EgorovFedor Fedorovich SeverinDmitry Borisovich ZorovElena Viktorovna StelmashukNikolai Konstantinovich IsaevNadezhda Anatolievna Kapay
A61P 25/28A61K 31/66A61K 31/444A61K 45/06A61P 25/00C09B 69/001A61K 47/54A61K 47/545C09B 11/24A61K 31/352
32
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for providing to a mammal a neuroprotective effect against a brain pathology that is associated with reactive oxygen species originating from mitochondria (mROS). The method includes the step of administering to the mammal an SkQ mitochondria-targeted antioxidant in an amount effective to provide said neuroprotective effect. The SkQ mitochondria-targeted antioxidant may be administered either prophylactically or for treatment with respect to brain pathologies other than brain trauma or stroke, and may be administered for treatment of brain trauma or stroke.

Claims

exact text as granted — not AI-modified
1 . A method for providing to a mammal a neuroprotective effect against a brain pathology that is mediated by reactive oxygen species originating from mitochondria (mROS), the method comprising the step of administering to the mammal an SkQ mitochondria-targeted antioxidant in an amount effective to provide said neuroprotective effect, wherein the SkQ mitochondria-targeted antioxidant is administered either prophylactically to inhibit the course of the pathology or for treatment of the pathology after its onset with the exception that, where the pathology is brain trauma or stroke, the SkQ mitochondria-targeted antioxidant is administered only for treatment after onset of the pathology. 
     
     
         2 . The method according to  claim 1 , wherein the brain pathology is selected from the group consisting of brain ischemia, impairment of synaptic plasticity in a hippocampus of the subject, alcohol intoxication, hyperhomocysteinemia, and brain trauma. 
     
     
         3 . The method according to  claim 1 , wherein the SkQ mitochondria-targeted antioxidant is selected from the group consisting of SkQ1 and SkQR1. 
     
     
         4 . The method according to  claim 1 , wherein the SkQ mitochondria-targeted antioxidant is administered to the mammal in an amount of about 1 pmole to 1 mmole per kg of body weight of the mammal per day. 
     
     
         5 . The method according to  claim 1 , wherein the brain pathology is brain ischemia. 
     
     
         6 . The method according to  claim 1 , wherein the brain pathology comprises the impairment of synaptic plasticity. 
     
     
         7 . The method according to  claim 1 , wherein the brain pathology comprises alcohol intoxication. 
     
     
         8 . The method according to  claim 7 , wherein the SkQ mitochondria-targeted antioxidant is administered to the mammal after the mammal has undergone alcohol narcosis. 
     
     
         9 . The method according to  claim 1 , wherein the brain pathology is hyperhomocysteinemia. 
     
     
         10 . The method according to  claim 9 , wherein the mammal is a pregnant human. 
     
     
         11 . The method according to  claim 1 , wherein the SkQ mitochondria-targeted antioxidant is administered to the mammal prior to an appearance in the subject of behavioral defects due to the brain pathology. 
     
     
         12 . The method according to  claim 1 , wherein the SkQ mitochondria-targeted antioxidant is administered to the mammal after the mammal has contracted the brain pathology or after an appearance in the subject of behavioral defects due to the brain pathology. 
     
     
         13 . The method according to  claim 1 , wherein the brain pathology is brain trauma. 
     
     
         14 . The method according to  claim 13 , wherein the SkQ mitochondria-targeted antioxidant is administered to the mammal daily after the mammal has experienced the brain trauma for a period of at least 4 days after the trauma. 
     
     
         15 . The method according to  claim 1 , wherein the SkQ mitochondria-targeted antioxidant is administered to the mammal by a mode of administration selected from the group consisting of intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intracerebral, intravaginal, transdermal, rectal, by inhalation and topical. 
     
     
         16 . The method according to  claim 1 , wherein the SkQ mitochondria-targeted antioxidant is administered to the mammal in combination with a glycolysis inhibitor. 
     
     
         17 . A method for providing to a mammal a neuroprotective effect against a brain pathology, the method comprising the step of administering to the mammal an SkQ mitochondria-targeted antioxidant in an amount effect to initiate an increased production of erythropoietin in the mammal. 
     
     
         18 . The method according to  claim 17 , wherein the brain pathology is selected from the group consisting of ischemia, trauma and Alzheimer's disease. 
     
     
         19 . A method for providing to a mammal a neuroprotective effect against a brain pathology, the method comprising the step of administering to the mammal an SkQ mitochondria-targeted antioxidant in an amount effect to cause a decrease in the activity of glycogen synthase kinase (GSK-3β) in the mammal. 
     
     
         20 . The method according to  claim 19 , wherein the brain pathology is selected from the group consisting of ischemia, trauma and Alzheimer's disease. 
     
     
         21 - 27 . (canceled)

Join the waitlist — get patent alerts

Track US2014329776A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.